Finoriq research workspace
Acurx Pharmaceuticals, Inc. (ACXP) Historical Metrics
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to. Review ACXP fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
- Company
- Acurx Pharmaceuticals, Inc. (ACXP)
- Ticker
- ACXP
- Market Cap
- $6.5M
- Latest Price
- $1.52
- Industry
- Biotech & Pharma
Acurx Pharmaceuticals, Inc. (ACXP) Current Valuation Metrics
Static valuation preview for Acurx Pharmaceuticals, Inc. (ACXP). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -121.6% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -99.6% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.88x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.